





Main focus


- Why we work on groups of substances
- How we work on groups of substances
- Where can you find more information?
- Things to remember

Why we work on groups of substances





Integrated Regulatory Strategy







Chemical universe mapping

Every **registered** substance mapped to **one** regulatory 'pool' based on planned, ongoing or concluded **regulatory actions**



(Data: Dec. 2020)





Why we work on groups?


- For many substances of (potential) concern, relevant regulatory actions are already ongoing – on the substance itself or on related substances
- Benefits:
 - Treats related substances consistently
 - Targets the right substances at the right time
 - Pools information which may allow faster action despite data gaps
 - Increases predictability of authorities' actions
 - Supports informed substitutions, or avoids regrettable substitutions
- → Preparatory work to support REACH & CLP processes

How we work on groups of substances





Work on groups



In this context, groups are not:

- registrants' read-across/ categories
- groups in regulatory processes

Risk management ongoing

Currently no further actions proposed





Iterative assessment


- First assessment at screening level
 - Hazards
 - Uses/exposure
 - Group boundaries (and need for subgrouping)
 - Potential for substitution
 - Initial assessment of regulatory needs: immediate action and expected further regulatory actions for whole group, (sub)group or individual substances
- Then, usually data generation or "currently no action" is proposed – in some cases, risk management is already possible
 - Assessment of read-across/category approach is only done during official processes (e.g. compliance check)
- Depth of assessment and knowledge on substances will increase in further iterations





Foreseen regulatory needs

- Plan for the longer-term regulatory risk management measures – beyond next action
- Longer-term regulatory need may be revised (e.g. when data is generated)
 - Regulatory needs will be reconsidered also for substances for which there is "currently no EU regulatory risk management needed" when further information becomes available



Where can you find more information?





More information


- Annual <u>IRS Report</u>
 - Progress in identifying and addressing substances of concern
 - Chemical universe
 - Statistics
 - Case studies



- Publication of assessments of regulatory needs
 - → Report (pdf) on currently expected regulatory needs and proposed immediate actions for all substances in a group
 - Increased transparency and predictability of our work
 - Published from end of 2021

echa.europa.eu

Things to remember







Things to remember

- Doing more, faster
 - Ten times more substances assessed in 2020 compared to previous years before ECHA started work on groups
- Consistent, holistic, predictable
 - Better integration of regulatory processes
 - Minimising regrettable substitution
- Update your registrations proactively (hazards, uses, volumes) and follow the publication of the assessments of regulatory needs on our website



Thank you!

jonathan.kuster(at)echa.europa.eu

Follow our news

News: echa.europa.eu/subscribe Facebook: @EUECHA

LinkedIn: European Chemicals Agency

Twitter: @EU_ECHA

YouTube: EUchemicals